John Logan Black, M.D., explains how Mayo Clinic Laboratories'
UGT1A1 tests (Mayo IDs:
U1A1Q and
UGTFZ) identify genetic variants that increase the risk of potentially life-threatening reactions to irinotecan, a chemotherapy agent.
(
00:32)
Could you give us a brief overview about your background and yourself?
(
02:16)
Could you explain the role of the
UGT1A1 gene and its significance in the pharmacogenomics of irinotecan?
(
05:34)
What specific tests do we offer for
UGT1A1 at Mayo Clinic Laboratories?
(
08:01)
Can you clarify the difference between targeted genotyping and full gene sequencing, and when each method is most appropriate?
(
10:36)
Could you elaborate on the specific clinical indications for testing in relation to irinotecan?
(
13:27)
How do
UGT1A1 test results impact the dosing of irinotecan? What should clinicians consider when using those results?
(
14:02)
Are there any other factors or related genes that should be considered alongside
UGT1A1, particularly for cancer therapy?